Acute Lung Injury is a life-threatening condition caused by severe acute hypoxemic respiratory failure. It is a key source of mortality and morbidity in critically ill patients without any evidence of hydrostatic pulmonary edema. Symptoms observed in acute lung injury include severe shortness of breath, low blood pressure, confusion, and extreme tiredness. This type of injury has a substantial impact on public health, with a high incidence across the world and it requires administration of a fast and goal-oriented therapy to suppress further lung damage.
DelveInsight’s “Acute Lung Injury Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Acute Lung Injury, historical and forecasted epidemiology as well as the Acute Lung Injury market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some Facts of Acute Lung Injury Market Report:
- The rising prevalence of acute lung injuries is expected to boost market growth over the forecast period.
- For instance, according to the National Heart, Lung, and Blood Institute, 79 people per 100,000 population per year developed acute lung injury (ALI), and 59 of these met the criteria for the more severe form of acute respiratory distress syndrome. The death rate of acute lung injury patients was around 38.5 %.
- Using the US census and assuming the same frequency throughout the country, 190,600 people per year develop ALI, and 74,500 dies off, or with, the disease in the US. Thus, the rising prevalence of acute lung injuries is driving the market.
Request for Free Sample Report: https://www.delveinsight.com/sample-request/acute-lung-injury-market
Some of Acute Lung Injury Companies are:
- Altor BioScience
- Apeiron Biologics
- Theravance Biopharma
- Viela Bio
- ReAlta Life Sciences
- Cantex Pharmaceuticals
- Asklepion Pharmaceuticals
- Stemedica Cell Technologies
- Forschung und Entwicklung
- FirstString Research
- Histocell S.L.
- GlaxoSmithKline
- S-Evans Biosciences
- CompleGen
- Commence Bio
- Windtree Therapeutics
- And Many Others
Request for Free Sample Report: https://www.delveinsight.com/sample-request/acute-lung-injury-market
Scope of Acute Lung Injury Market:
- The report covers the descriptive overview of Acute Lung Injury, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
- Comprehensive insight has been provided into the Acute Lung Injury epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for Acute Lung Injury are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of Acute Lung Injury market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Acute Lung Injury market
Some of Acute Lung Injury Therapies are:
- APN01
- TD-0903
- VIB7734
- RLS 0071
- Dociparstat sodium
- L-citrulline
- And Many Others
Request for Free Sample Report: https://www.delveinsight.com/sample-request/acute-lung-injury-market
Key Acute Lung Injury Market Questions:
- What was the Acute Lung Injury market share (%) distribution in 2017 and how it would look like in 2030?
- What would be the Acute Lung Injury total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
- What are the key findings pertaining to the market across 7MM and which country will have the largest Acute Lung Injury market size during the forecast period (2017-2030)?
- At what CAGR, the Acute Lung Injury market is expected to grow in 7MM during the forecast period (2017-2030)?
- What would be the Acute Lung Injury market outlook across the 7MM during the forecast period (2017-2030)?
- What would be the Acute Lung Injury market growth till 2030, and what will be the resultant market Size in the year 2030?
- How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Request for Free Sample Report: https://www.delveinsight.com/sample-request/acute-lung-injury-market
Table of Contents:
1. Key Insights
2. Executive Summary of Acute Lung Injury
3. Competitive Intelligence Analysis for Acute Lung Injury
4. Acute Lung Injury: Market Overview at a Glance
5. Acute Lung Injury: Disease Background and Overview
6. Patient Journey
7. Acute Lung Injury Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Unmet Needs
10. Key Endpoints of Acute Lung Injury Treatment
11. Marketed Products
List to be continued in report
12. Emerging Therapies
List to be continued in report
13. Acute Lung Injury: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Acute Lung Injury
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/acute-lung-injury-market